Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-06-09Clinical Trial Update: BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis [Phase 2]
Biogen's BG00012 (dimethyl fumarate) Phase 2 combination trial in multiple sclerosis has completed, with results posted in June 2015.
-
CLINICAL_TRIALS trial_result · 2015-05-29Clinical Trial Update: Natalizumab (Tysabri) Re-Initiation of Dosing [Phase 3]
The Phase 3 trial of natalizumab (Tysabri) for relapsing-remission multiple sclerosis was terminated, with results posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-04-13Clinical Trial Update: Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis [Phase 2]
A Phase 2 trial evaluating SB683699 in relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2015-04-08Clinical Trial Update: Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells [Phase 1, Phase 2]
Phase 1/2 trial evaluating tolerance induction in relapsing-remitting multiple sclerosis using autologous peptide-coupled peripheral blood m…
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses [Phase 2]
This completed Phase 2 study updates the long-term safety and efficacy of teriflunomide (HMR1726) in relapsing multiple sclerosis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-03-19Clinical Trial Update: Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis [Phase 3]
This update reports safety and tolerability results from a Phase 3 trial of fingolimod in patients with relapsing-remitting multiple scleros…
-
CLINICAL_TRIALS trial_result · 2015-03-17Clinical Trial Update: Mass Balance Study of MT-1303 [Phase 1]
The document reports the completion of a Phase 1 mass balance study of MT-1303 in relapsing-remitting multiple sclerosis. The trial was spon…
-
CLINICAL_TRIALS trial_result · 2015-03-17Clinical Trial Update: Comparative Oral Bioavailability Study of MT-1303 [Phase 1]
Phase 1 study update evaluating the comparative oral bioavailability of MT-1303 in Relapsing-remitting Multiple Sclerosis has been completed…
-
CLINICAL_TRIALS trial_result · 2015-02-27Clinical Trial Update: POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler [Phase 2]
Phase 2 MRI-based trial for relapsing-remitting multiple sclerosis has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2015-02-20Clinical Trial Update: A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 [Phase 1]
This document reports a completed Phase 1 study evaluating the cardiac pharmacodynamics of MT-1303 in relapsing-remitting multiple sclerosis…
-
CLINICAL_TRIALS trial_result · 2015-02-16Clinical Trial Update: ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis [Phase 1]
Phase 1 clinical trial update for ATX-MS-1467 in relapsing-remitting multiple sclerosis; the study is completed and results have been posted…
-
CLINICAL_TRIALS trial_result · 2015-02-02Clinical Trial Update: Adherence Trial With MS LifeLines ® Services
The Adherence Trial With MS LifeLines Services sponsored by EMD Serono has been terminated.
-
CLINICAL_TRIALS trial_result · 2014-12-31Clinical Trial Update: An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS [Phase 4]
Phase 4 head-to-head trial comparing two marketed therapies for relapsing-remitting multiple sclerosis has completed, assessing efficacy and…
-
CLINICAL_TRIALS trial_result · 2014-12-25Clinical Trial Update: Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya [Phase 4]
A Phase 4 clinical trial evaluating immune function and MRI disease activity in relapsing-remitting multiple sclerosis patients switching fr…
-
CLINICAL_TRIALS trial_result · 2014-11-18Clinical Trial Update: A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients [Phase 4]
Phase 4, open-label, non-randomized clinical trial evaluating whether natalizumab improves ambulatory measures in relapsing-remitting multip…
-
CLINICAL_TRIALS trial_result · 2014-10-21Clinical Trial Update: Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 2, Phase 3]
Phase 2/3 clinical trial of natalizumab (BG00002, Tysabri) in Japanese participants with relapsing-remitting multiple sclerosis has complete…
-
CLINICAL_TRIALS trial_result · 2014-09-25Clinical Trial Update: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression [Phase 4]
A Phase 4 trial evaluated adding antidepressants to fingolimod in patients with relapsing-remitting multiple sclerosis and depression; the s…
-
CLINICAL_TRIALS trial_result · 2014-09-09Clinical Trial Update: Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) [Phase 1]
Phase 1 safety study of Natalizumab in multiple sclerosis has completed. The update highlights safety and tolerability data from this early-…
-
CLINICAL_TRIALS trial_result · 2014-08-13Clinical Trial Update: Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis [Phase 3]
A Phase 3 trial evaluating Rebif, Copaxone, and Tysabri for active Relapsing Remitting Multiple Sclerosis was terminated with results posted…
-
CLINICAL_TRIALS trial_result · 2014-08-08Clinical Trial Update: Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) [Phase 4]
This Phase 4 trial update assesses patient-reported outcomes in relapsing-remitting multiple sclerosis patients who switched to fingolimod 0…
-
CLINICAL_TRIALS trial_result · 2014-07-31Clinical Trial Update: Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
An update on a real-world study evaluating Rebif with a new formulation, focusing on safety, tolerability, and patient adherence in relapsin…
-
CLINICAL_TRIALS trial_result · 2014-07-16Clinical Trial Update: An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
This completed observational study evaluated adherence and persistence to Rebif therapy in relapsing-remitting multiple sclerosis and explor…
-
CLINICAL_TRIALS trial_result · 2014-06-27Clinical Trial Update: A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function
A completed proof-of-concept trial evaluating the effect of natalizumab (Tysabri) on bladder function in relapsing-remitting multiple sclero…
-
CLINICAL_TRIALS trial_result · 2014-06-04Clinical Trial Update: fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls
This completed trial used fMRI to compare brain activity related to treatment recommendations in recently diagnosed relapsing-remitting mult…
-
CLINICAL_TRIALS trial_result · 2014-06-02Clinical Trial Update: Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis [Phase 3]
This clinical trial update reports efficacy and safety results from a Phase 3 study of oral BG00012 (dimethyl fumarate) versus an active ref…